Key highlights
- Chugai and Osaka University's IFReC identified a subgroup of adult primary ITP patients with complement-driven platelet destruction.
- The study delineated three distinct mechanisms of platelet destruction in ITP.
- Researchers propose a simple, clinically feasible test to detect complement-activated ITP and select patients who may benefit from complement inhibitors.
Study
A collaborative study by Chugai and the Immunology Frontier Research Center (IFReC) at Osaka University's Department of Hematology and Oncology was published in the journal Blood and identified for the first time a subgroup of adult primary immune thrombocytopenia (ITP) patients in whom complement activation contributes to platelet destruction.
Findings
Researchers characterized three distinct mechanisms of platelet destruction in ITP and showed that complement activation is responsible for platelet loss in a defined patient subset.
Clinical implications
The results indicate a potential simple, clinically feasible test to detect complement-activated ITP and to select patients who may benefit from complement inhibitors, suggesting a new targeted approach to treatment.
